Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Lufepirsen by Amber Ophthalmics for Persistent Corneal Epithelial Defects: Likelihood of Approval
Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase II for Persistent Corneal Epithelial Defects. According to...
Data Insights
Lufepirsen by Amber Ophthalmics for Persistent Corneal Epithelial Defects: Likelihood of Approval
Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase III for Persistent Corneal Epithelial Defects. According to...